Alembic Pharmaceuticals Ltd

Alembic Pharma Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Alembic Pharmaceuticals Ltd

₹ 962 -0.62%
21 May - close price
alembic-india.com BSE: 533573 NSE: APLLTD
About

Alembic Pharmaceuticals is in the business of development, manufacturing, and marketing of Pharmaceuticals products i.e. Formulations and Active Pharmaceutical Ingredients.
The company has 3 R&D and 5 manufacturing facilities.

Key Points

Leading Pharma company[1] Alembic is among the top 25 players in domestic formulations market. The company has a portfolio of about 200 formulation brands, of which three are among the top 300 domestic formulation brands in India. It has a share of 1.5% in the domestic market.

Website BSE NSE
  • Market Cap ₹ 18,869 Cr.
  • Current Price ₹ 962
  • High / Low ₹ 1,304 / 725
  • Stock P/E 38.3
  • Book Value ₹ 264
  • Dividend Yield 1.14 %
  • ROCE 11.4 %
  • ROE 9.75 %
  • Face Value ₹ 2.00
Edit ratios

Pros

  • Company has been maintaining a healthy dividend payout of 40.2%

Cons

  • Stock is trading at 3.64 times its book value
  • The company has delivered a poor sales growth of 7.86% over past five years.
  • Company has a low return on equity of 10.3% over last 3 years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln

Part of BSE 500 BSE Healthcare Nifty 500 BSE SmallCap BSE Allcap

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025
1,318 1,177 1,354 1,310 1,307 1,332 1,479 1,588 1,475 1,476 1,580 1,406 1,571
1,152 1,152 1,109 1,086 1,138 1,167 1,271 1,251 1,186 1,184 1,321 1,226 1,400
Operating Profit 166 26 245 224 169 166 207 337 288 291 259 180 171
OPM % 13% 2% 18% 17% 13% 12% 14% 21% 20% 20% 16% 13% 11%
12 1 0 1 2 12 9 3 7 3 29 15 13
Interest 6 9 12 15 14 14 15 15 10 13 18 22 24
Depreciation 122 67 67 66 74 66 67 69 69 69 70 70 69
Profit before tax 50 -49 167 144 84 98 134 257 216 213 200 104 92
Tax % 16% 0% 12% 17% -55% 0% 0% 9% 7% 17% 17% 17% 18%
42 -49 146 119 131 98 134 233 202 176 166 86 75
EPS in Rs 2.11 -2.51 7.45 6.06 6.64 4.96 6.81 11.87 10.27 8.96 8.43 4.37 3.83
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
1,844 2,019 3,009 2,986 2,945 3,660 4,133 5,067 5,035 5,149 5,874 6,033
1,485 1,611 2,026 2,353 2,313 2,782 2,930 3,618 4,127 4,484 4,875 5,131
Operating Profit 359 408 983 633 633 879 1,203 1,449 909 665 999 901
OPM % 19% 20% 33% 21% 21% 24% 29% 29% 18% 13% 17% 15%
4 3 7 3 7 6 125 84 51 3 31 61
Interest 10 3 4 3 2 15 25 13 17 49 54 76
Depreciation 40 44 72 83 102 106 136 183 285 273 271 277
Profit before tax 312 363 914 550 535 765 1,167 1,338 658 346 704 609
Tax % 24% 21% 24% 22% 21% 20% 17% 18% 17% -0% 5% 17%
238 287 699 431 422 611 969 1,097 544 347 666 503
EPS in Rs 12.64 15.20 37.06 22.84 22.38 32.42 51.42 55.79 27.65 17.64 33.91 25.60
Dividend Payout % 24% 23% 11% 18% 18% 17% 19% 25% 36% 45% 32% 43%
Compounded Sales Growth
10 Years: 12%
5 Years: 8%
3 Years: 6%
TTM: 3%
Compounded Profit Growth
10 Years: 6%
5 Years: -13%
3 Years: -3%
TTM: -26%
Stock Price CAGR
10 Years: 6%
5 Years: 1%
3 Years: 8%
1 Year: 1%
Return on Equity
10 Years: 18%
5 Years: 13%
3 Years: 10%
Last Year: 10%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity Capital 38 38 38 38 38 38 38 39 39 39 39 39
Reserves 592 796 1,493 1,830 2,157 2,675 3,308 5,062 5,251 4,375 4,870 5,155
109 194 0 8 622 1,059 1,687 584 706 710 492 1,194
423 484 651 634 862 777 846 958 1,078 1,006 998 1,168
Total Liabilities 1,162 1,511 2,182 2,509 3,678 4,549 5,879 6,643 7,074 6,130 6,399 7,556
397 489 697 799 918 1,085 1,276 1,774 1,771 2,377 2,536 2,513
CWIP 21 83 92 348 741 1,107 1,570 2,183 2,304 601 524 837
Investments 33 33 37 103 299 506 833 343 219 229 227 260
711 906 1,355 1,259 1,720 1,850 2,199 2,344 2,779 2,922 3,112 3,946
Total Assets 1,162 1,511 2,182 2,509 3,678 4,549 5,879 6,643 7,074 6,130 6,399 7,556

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
263 180 848 327 305 809 540 1,388 545 730 773 227
-111 -199 -292 -511 -794 -754 -822 -837 -369 -461 -329 -636
-151 18 -276 -96 498 80 166 -534 -217 -261 -445 404
Net Cash Flow 1 -1 280 -280 9 135 -116 18 -40 8 -2 -6

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Debtor Days 52 61 45 57 77 54 69 30 72 85 83 90
Inventory Days 159 195 240 237 274 325 375 376 339 280 274 403
Days Payable 144 162 225 177 246 173 137 148 139 131 126 148
Cash Conversion Cycle 66 95 60 117 105 207 307 258 272 234 232 345
Working Capital Days 50 69 57 84 109 80 129 102 130 131 129 163
ROCE % 47% 41% 72% 32% 23% 24% 27% 25% 12% 7% 14% 11%

Shareholding Pattern

Numbers in percentages

9 Recently
Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025
69.61% 69.61% 69.61% 69.61% 69.61% 69.61% 69.61% 69.61% 69.61% 69.61% 69.61% 69.67%
5.94% 5.32% 4.99% 4.55% 4.34% 4.51% 4.52% 4.46% 4.32% 3.94% 4.17% 3.94%
12.15% 12.55% 12.76% 13.32% 13.65% 14.22% 14.51% 15.39% 15.47% 16.05% 16.05% 16.43%
12.30% 12.52% 12.64% 12.53% 12.39% 11.67% 11.36% 10.54% 10.61% 10.38% 10.17% 9.96%
No. of Shareholders 1,01,4571,03,8111,01,86499,52297,60789,55285,21276,56774,82991,42993,94491,336

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls